| Autor: |
Davies A; Cancer Research UK Centre, University of Southampton, Southampton, UK., Kater AP; Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands., Sharman JP; Willamette Valley Cancer Institute & Research Center & US Oncology, Eugene, OR 97401, USA., Stilgenbauer S; Comprehensive Cancer Center Ulm, Early Clinical Trials Unit (ECTU), Ulm, & Division of CLL, Department of Internal Medicine III, Ulm University, Ulm, Germany., Vitolo U; Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy., Klein C; Roche Innovation Center Zurich, Schlieren, Switzerland., Parreira J; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Salles G; Memorial Sloan Kettering Cancer Center, Department of Medicine, NY 10021, USA. |
| Abstrakt: |
The type II anti-CD20 antibody obinutuzumab has structural and mechanistic features that distinguish it from the first anti-CD20 antibody, rituximab, which have translated into improved efficacy in phase III trials in indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). These gains have been shown through improvements in, and/or increased durability of, tumor response, and increases in progression-free survival in patients with CLL or follicular lymphoma (FL). Ongoing research is focusing on the use of biomarkers and the development of chemotherapy-free regimens involving obinutuzumab. phase II trials of such treatment regimens have shown promise for CLL, FL and mantle cell lymphoma, while phase III trials have highlighted obinutuzumab as the antibody partner of choice for novel agents in first-line CLL treatment. |
